V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Alnylam Pharmaceuticals Executive Compensation (FY25)

ALNY · Executive and director compensation, fiscal 2025 only
Data as of September 7, 2026Latest filing (8-K): May 27, 2026
262 figures on this page: 251 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Yvonne Greenstreet was paid $14,867,600 in total compensation as Chief Executive Officer for fiscal 2025. Meanwhile, shareholders recorded 92.9% support for the say-on-pay proposal at the meeting held May 20, 2026 for fiscal 2025. Separately, the company reported a chief executive pay ratio of 48:1 for fiscal 2025, against median employee compensation of $312,180, and the disclosed peer group includes Biogen Inc., BioMarin Pharmaceutical Inc., Exact Sciences Corporation, Gilead Sciences, Inc. and Incyte Corporation, among others, and the company reported 5 named executive officers for fiscal 2025.
Chief executive, fiscal 2025
◇
Yvonne Greenstreet
Latest say-on-pay support
=
May 20, 2026
Chief executive pay ratio
◇
To the median employee

Frequently asked questions

Answers drawn from the data on this page.
Who is Alnylam Pharmaceuticals' chief executive and what were they paid?
Yvonne Greenstreet was paid $14,867,600 in total compensation as Chief Executive Officer for fiscal 2025.
What was Alnylam Pharmaceuticals' say-on-pay result?
Shareholders recorded 92.9% support for the say-on-pay proposal at the meeting held May 20, 2026 for fiscal 2025.
Which companies are in Alnylam Pharmaceuticals' peer group?
The disclosed peer group includes Biogen Inc., BioMarin Pharmaceutical Inc., Exact Sciences Corporation, Gilead Sciences, Inc. and Incyte Corporation, among others.
What is Alnylam Pharmaceuticals' chief executive pay ratio?
The company reported a chief executive pay ratio of 48:1 for fiscal 2025, against median employee compensation of $312,180.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Yvonne Greenstreet
Chief Executive Officer
◇—◇◇◇—◇◇
Jeffrey Poulton
Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Bryan Supran
Executive Vice President, Chief Legal Officer and Secretary
◇◇◇—◇—◇◇
Pushkal Garg
Executive Vice President, Chief Research and Development Officer
◇—◇◇◇—◇◇
Tolga Tanguler
Executive Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Bryan A. SupranRSU◇——◇——◇
Jeffrey V. PoultonPSU◇◇◇—◇—◇
Jeffrey V. PoultonOPTION◇——◇—◇◇
Jeffrey V. PoultonRSU◇——◇——◇
Pushkal GargRSU◇——◇——◇
Pushkal GargOPTION◇——◇—◇◇
Pushkal GargPSU◇◇◇—◇—◇
Tolga TangulerOPTION◇——◇—◇◇
Tolga TangulerPSU◇◇◇—◇—◇
Tolga TangulerRSU◇——◇——◇
Yvonne L. GreenstreetRSU◇——◇——◇
Yvonne L. GreenstreetPSU◇◇◇—◇—◇
Yvonne L. GreenstreetOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Tolga TangulerOption◇—◇02/28/2034
Option◇—◇02/22/2032
Option◇—◇02/26/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇03/02/2035
RSU◇◇——
Pushkal GargOption◇—◇02/26/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇02/22/2032
RSU◇◇——
Option◇—◇03/02/2035
RSU◇◇——
RSU◇◇——
Option◇—◇02/28/2034
Jeffrey PoultonRSU◇◇——
RSU◇◇——
Option◇—◇02/22/2032
Option◇—◇03/02/2035
Option◇—◇02/28/2034
Option◇—◇02/26/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Yvonne GreenstreetRSU◇◇——
RSU◇◇——
Option◇—◇02/26/2033
Option◇—◇02/22/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇02/28/2034
RSU◇◇——
Option◇—◇03/02/2035
Bryan SupranRSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael W. Bonney
◇◇◇———◇
Amy W. Schulman
Board chair
◇◇◇———◇
Colleen F. Reitan
◇◇◇———◇
Elliott Sigal, M.D., Ph.D
◇◇◇———◇
Peter N. Kellogg
◇◇◇———◇
Olivier Brandicourt, M.D
◇◇◇———◇
David E.I. Pyott
◇◇◇———◇
Dennis A. Ausiello, M.D
◇◇◇———◇
Carolyn R. Bertozzi, Ph.D
◇◇◇———◇
Margaret A. Hamburg, M.D
◇◇◇———◇
Phillip A. Sharp, Ph.D
◇————◇◇
Yvonne L. Greenstreet, M.D and Stuart A. Arbuckle served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Biogen Inc. BIIB
  • BioMarin Pharmaceutical Inc. BMRN
  • Exact Sciences Corporation EXAS
  • Gilead Sciences, Inc. GILD
  • Incyte Corporation INCY
  • Moderna, Inc. MRNA
  • Neurocrine Biosciences, Inc. NBIX
  • Regeneron Pharmaceuticals, Inc. REGN
  • United Therapeutics Corporation UTHR
  • Vertex Pharmaceuticals Incorporated VRTX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 20, 2026=◇◇◇
2024May 8, 2025=◇◇◇
2023May 16, 2024=◇◇◇
2022May 18, 2023=◇◇◇
2021May 18, 2022=◇◇◇
2020May 18, 2021=◇◇◇
2019May 6, 2020=◇◇◇
2018April 25, 2019=◇◇◇
2017May 10, 2018=◇◇◇
2016May 2, 2017=◇◇◇
2015May 3, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Alnylam Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Alnylam Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Alnylam Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Alnylam Pharmaceuticals' disclosed peer group is defensible, who names Alnylam Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
262 figures on this page: 251 cited to the filing that reported them, 11 calculated from figures it prints.
251 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001628280-26-038499
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001628280-26-023923
    CEO Pay Ratio · Compensation of Directors · DIRECTOR COMPENSATION · Grants of Plan-Based Awards · and 2 more sections
  3. 0001178670-25-000062
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001178670-24-000027
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001193125-23-151845
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001193125-22-157503
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001193125-21-169325
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001193125-20-139137
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001193125-19-122475
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-18-164173
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001157523-17-001455
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-16-582064
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Alnylam Pharmaceuticals executive compensation, FY2025.” https://intel.velarion.ai/comp/ALNY (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Alnylam Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Alnylam Pharmaceuticals discloses

The companies named in ALNY's own disclosed peer group.

Biogen Inc.BioMarin Pharmaceutical Inc.Gilead Sciences, Inc.Incyte CorporationModerna, Inc.Neurocrine Biosciences, Inc.Regeneron Pharmaceuticals, Inc.United Therapeutics CorporationVertex Pharmaceuticals Incorporated

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy